
Vistim Labs enables clinicians to monitor dementia progression and treatment response using a single, noninvasive EEG. Their SaaS neurodiagnostic platform, CASBA ATN+, uses AI, machine learning, and…

Vistim Labs enables clinicians to monitor dementia progression and treatment response using a single, noninvasive EEG. Their SaaS neurodiagnostic platform, CASBA ATN+, uses AI, machine learning, and…
Product: Ceregram — in-clinic EEG-based neurotherapeutic monitoring system
Use case: Tracks dementia progression and treatment response as low-cost biomarker alternative
Founded: 2021
Recent funding: Grant reported Jun 8, 2023
Team size: Approximately 15 employees
Monitoring and tracking progression of neurodegenerative and other brain disorders; enabling precision neurology and routine therapy monitoring.
2021
Biotechnology Research
10000
Grant reported on Crunchbase
“Alberta Innovates, Beresford Ventures, GoAhead Ventures, PharmStars, RK Hart Capital”
| Company |
|---|
Join the Team Bringing PET-Quality Brain Imaging into Every Alzheimer’s and Neurology Practice - Leadership Role in a Breakthrough MedTech Category
Vistim Labs is answering the neurology question that matters most: is therapy working? Studies show we can convert a routine EEG into high-resolution brain images — all without radiation and in-office. We seek a strong senior sales leader to help us bring this technology to patients so they can finally have the answers they need to receive effective therapy.
Clinics already use our technology, but we are still very new in the industry. This role is for a leader with a strong, active network of Alzheimer's private practice neurology clinics that they can leverage to hit the ground running.
Your number #1 metric is number of units sold. You are expected to close new accounts within the first month.
Why this is so important: patients need to know if their therapy is working and they SELECT providers based on how easy it is to get answers
Practices are desperate for affordable, accessible, radiation-free tools to monitor amyloid/tau clearance and disease progression. It is central to their trust building with patients. Right now, doctors have to refer patients to expensive, far away facilities. If the patients don't go, the trust is lost, which hurts their business and ability to attract new patients.
Early adopter feedback has been exceptional: visible before/after images drive patient engagement, retention, and confidence in expensive therapies. This is a new category with strong clinical evidence, live demos, and published validation — but limited brand awareness. You will help define the go-to-market playbook.
Your Role
You will directly contribute to a genuine breakthrough in dementia care. Every account you open helps dozens of patients avoid unnecessary radiation and uncertainty while giving neurologists objective tools they’ve never had before.
If you have the network, the leadership experience, and the fire to own sales for one of the most important neurodiagnostic advances in the last decade, please let us know.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,500+
New This Week